Gilead Sciences (GILD) Gets a Buy Rating from Mizuho Securities

In a report released yesterday, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences (GILDResearch Report), with a price target of $75.00. The company’s shares closed last Thursday at $61.61.

According to, Syed ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.3% and a 33.3% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.

Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $68.86, a 13.4% upside from current levels. In a report issued on April 28, Jefferies also maintained a Buy rating on the stock with a $72.00 price target.

See the top stocks recommended by analysts >>

Based on Gilead Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.59 billion and net profit of $19 million. In comparison, last year the company earned revenue of $6.42 billion and had a net profit of $1.73 billion.

Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GILD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.

Read More on GILD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More